5,849 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Tema Etfs LLC

Tema Etfs LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 5,849 shares of the biopharmaceutical company's stock, valued at approximately $4,166,000. Regeneron Pharmaceuticals comprises about 1.7% of Tema Etfs LLC's portfolio, making the stock its 22nd largest position.

Several other institutional investors have also modified their holdings of the company. Capital International Investors grew its position in shares of Regeneron Pharmaceuticals by 41.6% during the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after acquiring an additional 1,390,534 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Regeneron Pharmaceuticals by 6.8% during the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock worth $1,726,940,000 after acquiring an additional 155,369 shares during the last quarter. Dodge & Cox boosted its position in Regeneron Pharmaceuticals by 0.4% during the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock worth $1,653,543,000 after acquiring an additional 9,381 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Regeneron Pharmaceuticals by 63.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after acquiring an additional 810,144 shares during the period. Finally, Franklin Resources Inc. boosted its position in Regeneron Pharmaceuticals by 7.9% during the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock worth $1,456,864,000 after acquiring an additional 149,124 shares during the period. Institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on REGN. Truist Financial reduced their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. JPMorgan Chase & Co. decreased their target price on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a research report on Monday, March 31st. Cantor Fitzgerald started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 target price for the company. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 22nd. Finally, Royal Bank of Canada decreased their target price on shares of Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an "outperform" rating for the company in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $890.60.

Regeneron Pharmaceuticals Trading Up 3.1%

Shares of REGN traded up $18.25 during midday trading on Tuesday, hitting $614.79. The stock had a trading volume of 1,102,019 shares, compared to its average volume of 792,581. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $520.50 and a fifty-two week high of $1,211.20. The business has a 50-day simple moving average of $596.79 and a two-hundred day simple moving average of $679.72. The firm has a market cap of $66.38 billion, a P/E ratio of 16.06, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the previous year, the business earned $9.55 earnings per share. The business's quarterly revenue was down 3.7% compared to the same quarter last year. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.57%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.